Literature DB >> 27624808

Optimal tachycardia programming in ICDs : Recommendations in the post-MADIT-RIT era.

Carsten W Israel1, Tatsiana Burmistrava2.   

Abstract

Optimal implantable cardioverter-defibrillator (ICD) programming can reduce the incidence of inappropriate shock therapy and improve prognosis in patients with an ICD. Only after results from randomized trials became available was the "safety first" feeling overcome that mandated early shock therapy, waived the use of antitachycardia pacing and forced shock therapy after a time of 30 s expired, even if tachycardia discriminators would have withheld the therapy. The strong evidence to limit ICD therapy to longer ventricular tachycardia (VT) should not result in individually dangerous ICD programming, particularly in patients with a high risk of slow VT (known monomorphic VT, post VT ablation, during treatment with amiodarone, very dilated left ventricle). Monitoring zones may aid to detect unexpected slow VT and to explain symptoms such as presyncope without exposing the patient to an unnecessary risk of inappropriate therapy. This review summarizes our current knowledge on optimal ICD programming and explains exactly how we should program device parameters in practice in single- or dual-chamber ICDs by different manufacturers and in different groups of patients.

Entities:  

Keywords:  Implantable cardioverter-defibrillator; Shock therapy; Supraventricular tachycardia; Ventricular fibrillation; Ventricular tachyarrhythmia

Mesh:

Year:  2016        PMID: 27624808     DOI: 10.1007/s00399-016-0459-x

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  17 in total

1.  Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance.

Authors:  D Bänsch; M Castrucci; D Böcker; G Breithardt; M Block
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

2.  2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.

Authors:  Bruce L Wilkoff; Laurent Fauchier; Martin K Stiles; Carlos A Morillo; Sana M Al-Khatib; Jesús Almendral; Luis Aguinaga; Ronald D Berger; Alejandro Cuesta; James P Daubert; Sergio Dubner; Kenneth A Ellenbogen; N A Mark Estes; Guilherme Fenelon; Fermin C Garcia; Maurizio Gasparini; David E Haines; Jeff S Healey; Jodie L Hurtwitz; Roberto Keegan; Christof Kolb; Karl-Heinz Kuck; Germanas Marinskis; Martino Martinelli; Mark Mcguire; Luis G Molina; Ken Okumura; Alessandro Proclemer; Andrea M Russo; Jagmeet P Singh; Charles D Swerdlow; Wee Siong Teo; William Uribe; Sami Viskin; Chun-Chieh Wang; Shu Zhang
Journal:  Europace       Date:  2015-11-19       Impact factor: 5.214

3.  Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study.

Authors:  Mohammad Saeed; Ibrahim Hanna; Dionyssios Robotis; Robert Styperek; Leo Polosajian; Ahmed Khan; Joseph Alonso; Yelena Nabutovsky; Curtis Neason
Journal:  J Cardiovasc Electrophysiol       Date:  2013-09-24

4.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.

Authors:  Michael O Sweeney; Mark S Wathen; Kent Volosin; Ismaile Abdalla; Paul J DeGroot; Mary F Otterness; Alice J Stark
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

6.  Prognostic importance of defibrillator shocks in patients with heart failure.

Authors:  Jeanne E Poole; George W Johnson; Anne S Hellkamp; Jill Anderson; David J Callans; Merritt H Raitt; Ramakota K Reddy; Francis E Marchlinski; Raymond Yee; Thomas Guarnieri; Mario Talajic; David J Wilber; Daniel P Fishbein; Douglas L Packer; Daniel B Mark; Kerry L Lee; Gust H Bardy
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

7.  Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Authors:  Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094

8.  Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.

Authors:  Axel Kloppe; Alessandro Proclemer; Angel Arenal; Maurizio Lunati; José Bautista Martìnez Ferrer; Ahmad Hersi; Marcin Gulaj; Maurits C E F Wijffels; Elisabetta Santi; Laura Manotta; Lorenza Mangoni; Maurizio Gasparini
Journal:  Circulation       Date:  2014-05-16       Impact factor: 29.690

9.  Tachyarrhythmia Cycle Length in Appropriate versus Inappropriate Defibrillator Shocks in Brugada Syndrome, Early Repolarization Syndrome, or Idiopathic Ventricular Fibrillation.

Authors:  Woo Seok Lee; Jun Kim; Chang-Hee Kwon; Jin Hee Choi; Uk Jo; Yoo Ri Kim; Gi-Byoung Nam; Kee-Joon Choi; You-Ho Kim
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

10.  Monomorphic ventricular tachycardia in patients with Brugada syndrome: A multicenter retrospective study.

Authors:  Moisés Rodríguez-Mañero; Frédéric Sacher; Carlo de Asmundis; Philippe Maury; Pier D Lambiase; Andrea Sarkozy; Vincent Probst; Estelle Gandjbakhch; Jesús Castro-Hevia; Johan Saenen; Kengo Fukushima Kusano; Anne Rollin; Elena Arbelo; Miguel Valderrábano; Miguel A Arias; Ignacio Mosquera-Pérez; Richard Schilling; Gian-Battista Chierchia; Ignacio García-Bolao; Javier García-Seara; Jaime Hernandez-Ojeda; Tsukasa Kamakura; Luis Martínez-Sande; José Ramón González-Juanatey; Michel Haïssaguerre; Josep Brugada; Pedro Brugada
Journal:  Heart Rhythm       Date:  2015-10-29       Impact factor: 6.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.